Research and Markets has announced the addition of the "Chronic Pain - Pipeline Review, H2 2016" report to their offering.
Chronic Pain Chronic pain is an abnormal processing of pain where the original injury or cause of acute pain has resolved, but the warning system has failed to shut off. Chronic pain may originate with an initial trauma/injury or infection, or there may be an ongoing cause of pain. Symptoms include fatigue, sleeplessness, weakened immune system and disability. Medications (pain relievers), nerve blocks, or surgery are some treatments used for chronic pain.
Chronic Pain pipeline therapeutics constitutes close to 132 molecules. Out of which approximately 118 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 16, 15, 1, 56, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 2 molecules, respectively.
Chronic Pain - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/q7z7j6/chronic_pain
View source version on businesswire.com: http://www.businesswire.com/news/home/20161018006658/en/Business Wire
Last updated on: 18/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.